澳大利亚儿童基于短信的流感疫苗主动安全性监测
澳大利亚AusVaxSafety系统通过短信和邮件主动调查6月龄至4岁儿童接种季节性流感疫苗后3天内的不良事件。2015至2016年共纳入7402名儿童,未发现安全信号;同时接种其他疫苗者发热率7.5%高于单独接种流感疫苗者2.8%(p<.001),报告发热与就医强烈相关(OR 42.6,95%CI 25.6-71.0)。
要点
- 主动监测未发现流感疫苗安全信号或不良事件增多。
- 同时接种其他疫苗者发热率7.5%高于单独接种者2.8%(p<.001)。
- 报告发热与就医强烈相关(OR 42.6,95%CI 25.6-71.0)。
核心结论
- 主动参与者报告数据可及时提供疫苗品牌特异性安全信息。
- 监测系统对流感疫苗安全性监测特别有用,因其组分每年可能变化。
研究设计与样本
- 分析2015和/或2016年接种季节性流感疫苗的6月龄至4岁儿童的累积监测数据。
- 通过短信和/或邮件调查在哨点免疫接种诊所收集家长/照护者报告的接种后3天内不良事件。
- 回顾性数据来自2年,合并分析特定不良事件率,比较三价和四价流感疫苗安全性。
主要发现
- 共纳入7402名儿童,每个疫苗接种季每周报告数据,未检测到安全信号或不良事件过多。
- 同时接种疫苗的儿童发热更多(7.5% vs 2.8%;p < .001)。
- 同时接种脑膜炎球菌B疫苗者不良事件率最高:30.3%报告不良事件,而单独接种流感疫苗者为7.3%(p < .001)。
- 报告发热与就医强烈相关(OR:42.6;95%CI:25.6-71.0)。
- 三价和四价流感疫苗安全性特征包括低且可预期的不良事件率(发热:三价4.3% vs 四价3.2%(p = .015);注射部位反应:三价1.9% vs 四价3.0%(p < .001))。
关键数值与推荐
- 不良事件定义为接种后3天内发生。
- 严重不良事件以就医作为替代指标。
- 发热:三价4.3% vs 四价3.2%(p = .015)。
- 注射部位反应:三价1.9% vs 四价3.0%(p < .001)。
临床怎么用
- 主动参与者报告数据可及时提供疫苗品牌特异性安全信息。
- 监测系统对流感疫苗安全性监测特别有用,因其组分每年可能变化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Australia's novel, active surveillance system, AusVaxSafety, monitors the post-market safety of vaccines in near real time. We analysed cumulative surveillance data for children aged 6 months to 4 years who received seasonal influenza vaccine in 2015 and/or 2016 to determine: adverse event following immunisation (AEFI) rates by vaccine brand, age and concomitant vaccine administration. METHODS: Parent/carer reports of AEFI occurring within 3 days of their child receiving an influenza vaccine in sentinel immunisation clinics were solicited by Short Message Service (SMS) and/or email-based survey. Retrospective data from 2 years were combined to examine specific AEFI rates, particularly fever and medical attendance as a proxy for serious adverse events (SAE), with and without concomitant vaccine administration. As trivalent influenza vaccines (TIV) were funded in Australia's National Immunisation Program (NIP) in 2015 and quadrivalent (QIV) in 2016, respectively, we compared their safety profiles. RESULTS: 7402 children were included. Data were reported weekly through each vaccination season; no safety signals or excess of adverse events were detected. More children who received a concomitant vaccine had fever (7.5% versus 2.8%; p < .001). Meningococcal B vaccine was associated with the highest increase in AEFI rates among children receiving a specified concomitant vaccine: 30.3% reported an AEFI compared with 7.3% who received an influenza vaccine alone (p < .001). Reported fever was strongly associated with medical attendance (OR: 42.6; 95% Confidence Interval (CI): 25.6-71.0). TIV and QIV safety profiles included low and expected AEFI rates (fever: 4.3% for TIV compared with 3.2% for QIV (p = .015); injection site reaction: 1.9% for TIV compared with 3.0% for QIV (p < .001)). There was no difference in safety profile between brands. DISCUSSION: Active participant-reported data provided timely vaccine brand-specific safety information. Our surveillance system has particular utility in monitoring the safety of influenza vaccines, given that they may vary in composition annually.
引用
- Pillsbury A, Quinn H, Cashman P, et al. Active SMS-based influenza vaccine safety surveillance in Australian children. Vaccine. 2017. PMID: 29128379. doi:10.1016/j.vaccine.2017.10.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。